# Immunai

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immunai

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.immunai.com
- Total disclosed funding: $285M
- Latest round: Series C (Oct 27, 2021)
- Investors on record: 12

## About

Immunai Inc. is a New York-based biotechnology company focused on decoding immunity by mapping the immune system, utilizing advanced techniques and comprehensive data integration to drive therapeutic advancements.Founded in 2018 in New York, US, Immunai Inc. specializes in decoding immunity through its innovative platform. The company has undergone strategic pivots to enhance its focus on multiomic data integration. The founders include Ansuman Satpathy, Danny Wells, and Luis Voloch, while Noam Solomon serves as CEO. In October 2021, Immunai raised USD 219 million in Series C funding, led by Koch Disruptive Technologies, with participation from notable investors including 8VC and Alexandria Venture Investments, bringing the total amount raised to USD 219 million and the current valuation to USD 1,024.70 mn.Immunai's offerings center around its advanced platform for decoding immunity, utilizing high-quality multiomic data from clinical and preclinical samples. Key solutions include Target Discovery for identifying disease-related targets, Preclinical Evaluation for prioritizing drug candidates, and Clinical Trial Optimization for enhancing drug understanding. The company caters to a diverse client base, including leading biopharmaceutical firms and research institutions across North America, Europe, and parts of Asia, focusing on next-generation immune-related therapeutics.Immunai generates revenue through partnerships and collaborations with biopharmaceutical companies and research institutions, offering subscription-based access to its platform and data services. Clients enter into multi-year agreements for these services, including consultations leveraging Immunai's machine learning expertise. Revenue models are structured around the complexity of services provided, aiming to deliver actionable insights that facilitate drug discovery and development processes.Following its recent funding round in October 2021, Immunai plans to utilize the USD 219 million raised to expand its drug actuary platform for target validation and evaluation. The company aims to launch new products designed to enhance capabilities in immune-related drug discovery. Additionally, Immunai is targeting expansion in new markets, focusing on increasing its presence in Europe and Asia by 2023.

## Funding rounds

- Series C, Oct 27, 2021, $219M — Alexandria Venture Investments, 8VC, Piedmont Capital Partners, Icon Capital, Koch Disruptive Technologies, Talos VC
- Series B, Feb 11, 2021, $60M — Viola Group, Duquesne Family Office, TLV Partners, Dexcel Pharma Technologies Ltd., Schusterman Family Office, Catalio Capital Management
- Seed, May 15, 2020, $5.5M — Viola Group, TLV Partners

## Investors

- Viola Group (https://capitalatlas.ai/funds/viola-group) — Seed, Series B
- TLV Partners (https://capitalatlas.ai/funds/tlv-partners) — Seed, Series B
- Duquesne Family Office — Series B
- Dexcel Pharma Technologies Ltd. — Series B
- Schusterman Family Office — Series B
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series C
- 8VC (https://capitalatlas.ai/funds/8vc) — Series C
- Piedmont Capital Partners — Series C
- Icon Capital (https://capitalatlas.ai/funds/icon-capital) — Series C
- Koch Disruptive Technologies (https://capitalatlas.ai/funds/koch-disruptive-technologies) — Series C
- Talos VC (https://capitalatlas.ai/funds/talos-vc) — Series C